SPOTLIGHT -
Perspectives: Youth and Physician Attitudes Towards Firearm Injury Prevention
Read about opinions and events in firearm injury prevention among adolescents and clinicians.
In Memoriam: Warren Brodey, MD, and Psychiatry as a Many-Splendored Thing
Warren Brody, MD: Ahead of his time? Remembering his life and legacy.
Clinical Reflections on the SSRI and Pregnancy FDA Panel
Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.
OpenAI Finally Admits ChatGPT Causes Psychiatric Harm
OpenAI acknowledges ChatGPT's risks to psychiatric patients and commits to improving safety measures, but skepticism about their sincerity remains.
Positive Phase 2 Results: Psilocybin-Assisted Psychotherapy Treatment, PSX-001, for Generalized Anxiety Disorder
Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.
The New Risk Factor: AI Influence and Psychiatric Vulnerability
Reflect on the risk artificial intelligence poses to psychiatric patients and the ethical questions that arise from this new technology.
Psychiatry and Spirituality: Exploring the Intersections of Meaning and Mental Health
In this CME, learn about the convergence of neuroscience and spirituality.
Return of the Soul: The Role of Spirituality in Mental Health
Most of the US population—nearly 80%—endorse spiritual and/or religious beliefs. How can these beliefs be applied to psychiatry?
Leqembi for Alzheimer Disease Launches in First European Union Countries
Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.
Jacques Lacan: Hiding in Plain Sight
Explore Jacques Lacan's revolutionary psychoanalytic theories, including the Imaginary, Symbolic, and Real registers, reshaping our understanding of identity and desire.
The Week That Was Hurricane Katrina and 20 Years of Ensuing Climate Change
It's been 20 years since Hurricane Katrina. What lessons have we learned and what lessons do we still need?
Beyond Compliance: Addressing Indigenous Mental Health and What Is Missing in Clinical Practice
Indigenous communities experience disproportionate rates of trauma, mental illness, poverty, and institutional mistrust.
Lithium, Alzheimer Disease, and a Turning Point in Mental Health Care
New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.
Database Lock in Trial for New At-Home Treatment of Agitation in Bipolar Disorders and Schizophrenia
BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.
The Current Legal and Research Status on AI and Psychotherapy
According to a new law, humans are essential for appreciating nonverbal information and exercising ethical priorities.
Beyond Representation: Rethinking Emotional Asymmetry in Psychiatric Diversity Models
Psychiatry confronts emotional asymmetry, revealing how race and privilege shape emotional expression and affective labor in clinical settings.
Top 3 Studies on Athletes’ Mental Health from Around the Globe: Insights from the Second Quarter of 2025
Explore the latest research on athlete mental health, highlighting concussion recovery, anti-doping stress, and the protective role of competitive sports.
Optimizing Cognition and Functioning Before Evaluating Capacity
Understanding decisional capacity is crucial for effective patient care, emphasizing the need for tailored assessments and support to enhance autonomy.
A Yale Medical School Student Research Project on Therapeutic Communities 55 Years Later
Explore the lasting impact of therapeutic communities on mental health and addiction recovery, highlighting innovative research and community-building strategies.
More Than Diverse: Race as an Insufficient Proxy of American Historic Lived Expertise
An expert shares the importance of lived expertise in addressing health care inequities and fostering a deeper understanding of diversity in medical practices.
Maternal Health Is Fetal Health: A Response to the FDA's SSRI Panel Discussion
Untreated maternal mental health issues during pregnancy pose significant risks. Informed discussions on medication are crucial for mother and baby's well-being.
Far More Than Diversity: What the Field of Medicine Needs
The August Special Report emphasizes the urgent need for action beyond diversity in psychiatry, addressing systemic racism's profound impact on Black mental health.
Borderline Personality Disorder Without DBT? Absolutely.
Discover effective strategies for treating borderline personality disorder without intensive therapy, focusing on empowerment, structure, and human connection.
Hepatitis-C Virus Found to Be Associated With Schizophrenia and Bipolar Disorder
FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder
Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.
The Terrible Narcissistic Triad: Addressing Hubris, Humiliation, and Revenge in War and Peace
H. Steven Moffic, MD, examines the psychological dynamics of hubris, humiliation, and revenge in global conflicts.
Optimizing Narcolepsy Management: A Clinical Update
Explore effective strategies for managing narcolepsy, including personalized treatment plans, medication options, and lifestyle interventions for improved patient outcomes.
How Our Past Trauma Drives Our Brain’s Response to New Stress
New research reveals how past trauma influences brain responses to stress, highlighting the importance of neural connectivity in mental health and coping strategies.
Risk Factors for Catatonia Relapse in Psychotic and Affective Disorders
Nearly half of catatonia patients relapse within two years, highlighting the need for effective long-term management strategies and potential benefits of antipsychotics.
BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia: Positive Pre-sNDA Meeting With FDA
BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.
